Collection of Blood Samples for New Diagnostic Devices 2
NCT ID: NCT05568966
Last Updated: 2023-12-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
20000 participants
INTERVENTIONAL
2022-07-11
2026-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research activities will be completed on blood samples collected from a maximum of 20,000 patients to assess the performance of the new biomarkers undergoing research. Patients will include those presenting at a medical unit (including but not limited to A\&E departments, hospital wards, or out-patient clinics) to their care team, in order to obtain a range of values for research of the new biomarkers on the LumiraDx system. Participants will include those who are expected to have (but are not limited to) biomarkers for diseases areas including embolism, infection or inflammation, cardiovascular, and renal cohorts.
Each patient must give appropriate written informed consent and satisfy all the inclusion/exclusion criteria prior to any study procedures. Patient participation in this study will take a maximum of 45 minutes of the patient's time. Patients presenting for a subsequent clinic visit or admission may be approached to participate in the study again, a maximum of 24mL of venous whole blood and up to 6 capillary fingersticks (obtained with a high flow lancet) may be collected from each patient within a three month period. Where possible, study samples should be taken at the same time as any standard of care blood draws or from patients with a cannula in-situ, a separate study venipuncture is not a requirement for this protocol. Study samples will be used for research, evaluation, optimisation and development activities into new biomarkers on the LumiraDx Platform in comparison with the gold standard reference method for the disease area to ensure comparable performance. Samples may also be used for troubleshooting and calibrating LumiraDx assays developed.
Sample collection will be separated into 2 phases depending upon the research needs. Patients can participate in both phases:
Phase 1: Only venous blood samples will be drawn by the HCP. These samples will be tested on the LumiraDx System and/or device(s) under development and also tested on the appropriate reference method for comparison. This testing may occur at the clinical site and/or at LumiraDx UK Ltd.
Phase 2: Venous blood samples and capillary fingerstick samples will be collected by the HCP. These samples may be tested on the LumiraDx Platform and also tested on the appropriate reference method for comparison. The fingerstick samples will be tested on the LumiraDx device. The processing of samples may occur at the clinical site and/or at LumiraDX UK Ltd.
The samples will be identified by patient identification number, anonymising the patient's identifiable information. These blood samples will be sent to LumiraDx UK Ltd for storage and future testing. No genetic testing will be carried out on samples. Samples may also be used to research, optimise, develop, modify and calibrate products and platforms for measuring biomarkers including, but not limited to, Troponin, NT-pro BNP, BNP, CK-MB, D-Dimer, NGAL, Cystatin C, Myoglobin, Galectin-3, CRP, AST, ALT, Lipids, Coagulation, Prolactin, and Beta-hCG.
Patients who reattend or are admitted to the medical unit (including but not limited to A\&E departments, hospital wards or out-patient clinics) may be asked for further sampling. A total of 24mL and 6 capillary fingersticks (obtained using high flow lancets) will not be exceeded over the three month period from consent, patients may opt out of further contact. Any patient reattending three months post consent will be treated as a new patient.
Data will be recorded on the Case Report Forms. The patient demographics data collected may include: age; sex; ethnicity, pregnancy status, NYHA classification, current medications at time of blood collection including their indications, significant medical history, relevant local blood test results, reason(s) for presenting, and confirmed diagnosis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Blood Draw
Venous blood draw up to 24mL and/or 6 capillary fingersticks
Interventions:
Diagnostic Test: Venepuncture Diagnostic Test: Fingerstick
Venous blood draw
Venepuncture to draw up to 24mL of venous blood.
Fingerstick
Capillary blood draw
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venous blood draw
Venepuncture to draw up to 24mL of venous blood.
Fingerstick
Capillary blood draw
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing and able to provide written informed consent and comply with study procedures.
* Patients attending a definitive care team with research capabilities which has been enroled in this collection study.
* Patients who can read and understand written English.
* The subject must present as one of the following cohorts:
1. Group A - Embolism Cohort - Patients presenting with symptoms indicative of thromboembolic events.
2. Group B - Infection or Inflammation Cohort - Patients presenting with symptoms indicative of infection or inflammatory disorders.
3. Group C - Cardiovascular Cohort - Patients presenting with symptoms indicative of heart failure or acute coronary syndrome.
4. Group D - Renal Cohort - Patients presenting with symptoms indicative of renal disorders.
5. Group E - Other Cohort. - Patients who are not eligible for any of the above groups.
Exclusion Criteria
* Vulnerable populations deemed inappropriate for the study by the sites Principal Investigator.
* Patients who have previously been enroled in any LumiraDx NOVEL study in the past 3 months and re-entry would breach the 24mL and or 6 fingersitck maximums.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
LumiraDx UK Limited
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Roy Gardner
Role: PRINCIPAL_INVESTIGATOR
NHS National Waiting Times Centre Board
Alasdair Gray
Role: PRINCIPAL_INVESTIGATOR
NHS Lothian
Allan Cameron
Role: PRINCIPAL_INVESTIGATOR
NHS Greater Glasgow & Clyde
David Lowe
Role: PRINCIPAL_INVESTIGATOR
NHS Greater Glasgow & Clyde
Santosh Bongale
Role: PRINCIPAL_INVESTIGATOR
NHS Greater Glasgow & Clyde
Fiona Hunter
Role: PRINCIPAL_INVESTIGATOR
NHS Lanarkshire
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Monklands
Airdrie, Scotland, United Kingdom
Royal Infirmary of Edinburgh
Edinburgh, Scotland, United Kingdom
St John's Hospital
Edinburgh, Scotland, United Kingdom
Glasgow Royal Infirmary
Glasgow, Scotland, United Kingdom
Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdom
Golden Jubilee National Hospital
Glasgow, Scotland, United Kingdom
Royal Alexandra Hospital
Paisley, Scotland, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Fiona Hunter
Role: primary
Alasdair Gray
Role: primary
Alasdair Gray
Role: primary
Allan Cameron
Role: primary
David Lowe
Role: primary
Roy Gardner
Role: primary
Santosh Bongale
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
S-CLIN-PROT-00025
Identifier Type: -
Identifier Source: org_study_id